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Biological samples collected in refugee camps during an outbreak of hepatitis E were used to compare the
accuracy of hepatitis E virus RNA ampliﬁcation by real-time reverse transcription-PCR (RT-PCR) for sera and
dried blood spots (concordance of 90.6%). Biological proﬁles (RT-PCR and serology) of asymptomatic indi-
viduals were also analyzed.
Hepatitis E virus (HEV) is a spherical, nonenveloped, sin-
gle-stranded RNA virus (2, 16) that belongs to the new genus,
Hepevirus (14). This pathogen is responsible for at least 50% of
acute non-A non-B hepatitis in developing countries, where it
causes sporadic infection but also large epidemics usually as-
sociated with fecal contamination of water (4–6, 10, 11, 15). A
large outbreak of hepatitis E was reported in June 2004 in the
internally displaced population camps of Darfur, in West Su-
dan, and across the border in Chad: at least 5,000 HEV infec-
tions were recorded from June to December 2004 (9). A task
force, set up by the nongovernmental organizations Me ´decins
Sans Frontie `res (Doctors Without Borders) and Epicentre in
refugee camps in Darfur and by the World Health Organiza-
tion and Centers for Disease Control in refugee camps in
Chad, conducted a ﬁeld study of this large epidemic. The
samples were drawn from both clinical patients and asymptom-
atic individuals (3, 9, 13). The French National Reference
Laboratory (CNR) for hepatitis E monitored the biological
and virological investigations. The aims of this study were to
assess the feasibility of amplifying HEV RNA from dried blood
spots (DBS) in comparison with ampliﬁcation from serum and
to describe the biological proﬁles of patients and asymptomatic
individuals.
Eighty-nine displaced persons living in the Chad Goz Amer
camp (median age, 28 years; range, 7 to 65 years) and 92
persons in the Sudanese Mornay camp (median age, 25 years;
range, 3 to 75 years) were investigated in August and Septem-
ber 2004. Two groups were deﬁned in each camp. The ﬁrst was
composed of patients considered to be HEV infected, i.e.,
patients presenting or having presented jaundice since 1 July
2004 and with negative test results for a malarial diagnosis (n 
36 in Goz Amer; n  56 in Mornay). The time before onset of
jaundice was reported by the physicians of medical teams after
investigation of patient histories. The second group included
individuals that were asymptomatic from the start of the out-
break (n  53 in Goz Amer; n  36 in Mornay). Two types of
biological samples were collected for each individual. First,
whole-blood samples were collected by venipuncture and were
centrifuged locally to isolate sera. Aliquots were conserved
between 4 and 8°C in the ﬁeld and at 80°C at CNR.
Second, ﬁnger-prick whole-blood samples were collected on
ﬁlter paper. The ﬁlter papers were thoroughly air dried and
were stored at ambient local temperatures (28 to 40°C) in
individual paper bags to prevent contamination and preserve
long-term stability. As various medical teams were involved,
two types of ﬁlter paper were used: Whatman paper in Goz
Amer and Isocode Stix in Mornay (Schleicher and Schuell
Bioscience, Inc.).
Samples were shipped to France, and serum samples were
tested for anti-HEV immunoglobulin G (IgG) and IgM with
enzyme-linked immunosorbent assay HEV IgG and HEV IgM
kits (Genelabs Diagnostics and Abbott). HEV RNA was am-
pliﬁed from DBS and serum samples from each refugee. Paper
sample areas were eluted in 220 l of phosphate-buffered
saline–Tween buffer. A ﬁnal elution or serum volume of 200 l
was used for nucleic acid extraction with a MagnA pure RNA
isolation kit (Roche Diagnostics). After a retrotranscription
step, HEV RNA was ampliﬁed and detected by consensus
TaqMan real-time reverse transcription-PCR (RT-PCR) per-
formed on a LightCycler as described previously (8). Samples
with a crossing point inferior to 43, without ampliﬁcation of the
negative control, were considered positive (8). Samples with
discordant results for serum and DBS were tested in duplicate
in two independent real-time PCR assays (retrotranscription
and PCR). HEV RNA ampliﬁcation results for sera and DBS
were concordant in 90.6% of cases (Table 1), with no statisti-
cally signiﬁcant differences (McNemar chi-square test). The
kappa correlation coefﬁcient was calculated as 0.808. The re-
sults of ampliﬁcation from DBS and sera were in agreement at
86.5% for Whatman paper and 94.6% for Isocode Stix. No
signiﬁcant difference between the two papers was observed in
this study (P  0.1). Thus, DBS are easy to collect and store
and have been successfully used for the ampliﬁcation of HEV
RNA by real-time RT-PCR. However, in nine cases, HEV
RNA was ampliﬁed in serum samples but not in DBS samples.
Six of the nine samples were stored on Whatman paper, and
the amount of blood on the ﬁlter was less than 50 l. Three of
the nine samples were collected on Isocode Stix in suitable
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 volumes, and discrepancies may be explained by persistence of
natural PCR inhibitors in the paper matrix or by RNases in-
troduced by ﬁnger contact when handling the papers during
collection. HEV ampliﬁcation sensitivity is dependent on stan-
dardizing the quantity of blood and on the careful handling of
ﬁlter papers with gloves, especially for this RNA virus. In eight
cases, DBS samples were positive and serum samples were
negative for HEV RNA ampliﬁcation; these cases occurred in
samples from patients with clinical and serological evidence of
acute hepatitis (n  3) and in samples from asymptomatic
refugees in which anti-HEV IgM was detected in the serum
(n  4). These cases, which provided the best results for HEV
ampliﬁcation from DBS samples, may be explained by the
degradation of RNA in sera due to an absence of cooler con-
ditions during transport (less than 20°C).
The second objective of this study was to describe the vari-
ous biological proﬁles identiﬁed. Among the group deﬁned as
hepatitis E cases, all the specimens were positive for at least
one of the HEV markers HEV RNA, anti-HEV IgG, and
anti-HEV IgM (Table 2). HEV RNA was detected in 65.1% of
cases; among these, 51 of 58 had detectable anti-HEV IgM.
The Abbott IgM anti-HEV assay had a sensitivity of 86% in
comparison with the results of RT-PCR. These results are
consistent with data reported under outbreak conditions (7,
12). Interestingly, HEV RNA ampliﬁcation was positive in 7 of
12 (58.3%) DBS specimens with negative anti-HEV IgM re-
sults, allowing the diagnosis of HEV infection. Conversely,
among the cases in which HEV RNA ampliﬁcation was nega-
tive (34.9%), 26 of 31 (83.9%) had detectable anti-HEV IgM.
These observations underline the importance of using different
biological tests for the HEV diagnosis, as none of the tests are
sufﬁciently sensitive for use alone. Interestingly, HEV viremia
was detectable with TaqMan HEV RNA real-time RT-PCR
for more than 39 days after the onset of jaundice. Another
point to underline is the large proportion of asymptomatic
individuals displaying a biological proﬁle consistent with acute
hepatitis E infection (43.5%), with a detectable viremia for
31.5% of cases (Table 3). No statistically signiﬁcant differences
were observed when comparing the ages of individuals with
icteric infections and those with asymptomatic HEV infections;
however, clinical observations have documented the frequency
of symptoms among older populations (1). An accurate eval-
uation of the spread of disease and the infection attack rate
also requires biological samples from a cross section of asymp-
tomatic individuals.
DBS have already been used for PCR detection of hepato-
tropic viruses, but this study is the ﬁrst report using real-time
nucleic acid ampliﬁcation of DBS collected under tropical con-
ditions in refugee camps during an outbreak. DBS requires
only 50 l of blood, which is an advantage for children. DBS
samples do not require a centrifuge and can be mailed unre-
frigerated with a low biohazard risk. Thus, RT-PCR of DBS
samples may provide an accurate and reliable tool for conduct-
ing ﬁeld studies of outbreaks in developing countries.
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